Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reem Karmali

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
Hematology. American Society of Hematology. Education Program|December 10, 2021
Relapsed disease: off-the-shelf immunotherapies vs customized engineered productsReem Karmali
Journal of Personalized Medicine|March 25, 2022
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK InhibitorsMadelyn Burkart, Reem Karmali
Blood|July 6, 2019
Revving up the immune engine in cHLReem Karmali, Leo I Gordon
Blood|February 13, 2025
Mosunetuzumab next up to bat … is it a home run?Reem Karmali, Jane N Winter
Immunotherapy|October 14, 2025
Exploring new treatment strategies for hard-to-treat double-hit and double-expressor lymphomasMax F Kelsten, Reem Karmali
Current Treatment Options in Oncology|February 24, 2017
Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision TherapyReem Karmali, Leo I Gordon
The Lancet. Haematology|December 25, 2025
Sequencing T-cell therapy for relapsed or refractory large B-cell lymphomaReem Karmali, Leo I Gordon
F1000Research|August 16, 2018
Current overview and treatment of mantle cell lymphomaMichael Schieber, Leo I Gordon, Reem Karmali
Cancers|January 23, 2024
Harnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable CancersAmber Willbanks, Mina Seals, Reem Karmali, et al.
Future Oncology (London, England)|May 2, 2023
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphomaReem Karmali, Frederique St-Pierre, Leo I Gordon
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
Hematology. American Society of Hematology. Education Program|December 10, 2021
Relapsed disease: off-the-shelf immunotherapies vs customized engineered productsReem Karmali
Journal of Personalized Medicine|March 25, 2022
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK InhibitorsMadelyn Burkart, Reem Karmali
Blood|July 6, 2019
Revving up the immune engine in cHLReem Karmali, Leo I Gordon
Blood|February 13, 2025
Mosunetuzumab next up to bat … is it a home run?Reem Karmali, Jane N Winter
Immunotherapy|October 14, 2025
Exploring new treatment strategies for hard-to-treat double-hit and double-expressor lymphomasMax F Kelsten, Reem Karmali
Current Treatment Options in Oncology|February 24, 2017
Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision TherapyReem Karmali, Leo I Gordon
The Lancet. Haematology|December 25, 2025
Sequencing T-cell therapy for relapsed or refractory large B-cell lymphomaReem Karmali, Leo I Gordon
F1000Research|August 16, 2018
Current overview and treatment of mantle cell lymphomaMichael Schieber, Leo I Gordon, Reem Karmali
Cancers|January 23, 2024
Harnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable CancersAmber Willbanks, Mina Seals, Reem Karmali, et al.
Future Oncology (London, England)|May 2, 2023
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphomaReem Karmali, Frederique St-Pierre, Leo I Gordon
Pageof 14